SINTILIMAB PLUS CHEMOTHERAPY IN UNRESECTABLE GASTRIC/GEJ CANCER: A RETROSPECTIVE SAFETY AND EFFICACY ANALYSIS
Keywords:
Gastric cancer, Gastroesophageal junction cancer, Sintilimab, ImmunotherapyAbstract
To compare overall survival and safety of patients with metastatic gastric and gastroesophageal junction cancers treated with sintilimab with chemotherapy vs. chemotherapy only. In this study, we enrolled 60 with metastatic gastric cancer patients. Among them, 33 received treatment with chemotherapy combined with sintilimab, while the other 27 received chemotherapy alone. Demographic, clinical, and pathological data were analyzed. Of the 60 patients, 27 were treated with sintilimab plus chemotherapy and 33 with chemotherapy only. The addition of sintilimab increased the tumor response rate to chemotherapy (disease control rate [DCR]: 96.29% vs. 72.72%, P = 0.017). Furthermore, the combination therapy improved the progression-free survival (median: 8.41 months [95% CI: 5.59-11.22] vs. 6.03 months [95% CI: 3.90-8.16]) and overall survival (31.46 months [95% CI: 24.69-38.22] vs. 23.38 months [95% CI: 17.34-29.43]). Overall, the combined treatment group demonstrated good treatment tolerance. In patients with metastatic gastric and gastroesophageal junction cancers receiving first-line chemotherapy, the addition of sintilimab improved treatment outcomes compared with chemotherapy alone.References
[1] Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2] Shah M A, Bang Y J, Lordick F, et al. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. JAMA Oncology, 2017, 3(5): 620-627. DOI: 10.1001/jamaoncol.2016.5580.
[3] Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Annals of Oncology, 2019, 30(1): 19-33. DOI: 10.1093/annonc/mdy502.
[4] Vafaei S, Zekiy A O, Khanamir R A, et al. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell International, 2022, 22(1): 2. DOI: 10.1186/s12935-021-02407-8.
[5] Janjigian Y Y, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet, 2021, 398(10294): 27-40. DOI: 10.1016/S0140-6736(21)00797-2.
[6] Shitara K, Van Cutsem E, Bang Y J, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncology, 2020, 6(10): 1571-1580. DOI: 10.1001/jamaoncol.2020.3370.
[7] Kang Y K, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 2017, 390(10111): 2461-2471. DOI: 10.1016/S0140-6736(17)31827-5.
[8] Shiravand Y, Khodadadi F, Kashani S M A, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology, 2022, 29(5): 3044-3060. DOI: 10.3390/curroncol29050247.
[9] Zhang L, Mai W, Jiang W, et al. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Frontiers in Oncology, 2020, 10: 594558. DOI: 10.3389/fonc.2020.594558.
[10] Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer, 2009, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026.
[11] Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncology, 2017, 18(3): e143-e152. DOI: 10.1016/S1470-2045(17)30074-8.
[12] Qin S, Guo J, Li J, et al. Management of immune checkpoint inhibitor-related toxicity of the Chinese Society of Clinical Oncology (CSCO). People's Medical Publishing House, 2019: 1-116.
[13] National Comprehensive Cancer Network. Management of immunotherapy-related toxicities version 2.2019 NCCN clinical practice guidelines in oncology (NCCN guidelines). 2019.
[14] Ajani J A, D'Amico T A, Bentrem D J, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 2022, 20(2): 167-192. DOI: 10.6004/jnccn.2022.0008.
[15] Xu J, Jiang H, Pan Y, et al. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial. JAMA, 2023, 330(21): 2064-2074. DOI: 10.1001/jama.2023.19918.
[16] Chen Z, Chen Y, Sun Y, et al. Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data. Signal Transduction and Targeted Therapy, 2024, 9(1): 222. DOI: 10.1038/s41392-024-01932-y.
[17] Zhao Y, Li D, Zhuang J, et al. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial. Clinical and Translational Medicine, 2024, 14(5): e1674. DOI: 10.1002/ctm2.1674.